BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 2912403)

  • 21. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Church T; Yurgalevitch S; Austin JH; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Jul; 97(13):989-97. PubMed ID: 15998952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
    Sharma VK; Corder FA; Fancher J; Howden CW
    Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evaluation of various screening and surveillance methods in colorectal carcinoma].
    Burchert A; Schmassmann A
    Schweiz Med Wochenschr; 1998 Jun; 128(25):999-1011. PubMed ID: 9691335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
    Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
    J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population colorectal cancer screening with fecal occult blood test.
    Rennert G; Rennert HS; Miron E; Peterburg Y
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for colorectal cancer--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1999 Feb; 48(6):116-21. PubMed ID: 10073920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 25-year follow-up of a population screened with faecal occult blood test in Finland.
    Malila N; Hakama M; Pukkala E
    Acta Oncol; 2007; 46(8):1103-6. PubMed ID: 17851857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The case for population-based screening for colorectal cancer.
    Schoen RE
    Nat Rev Cancer; 2002 Jan; 2(1):65-70. PubMed ID: 11902587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acceptability and compliance in screening for colorectal cancer with fecal occult blood test.
    Adamsen S; Kronborg O
    Scand J Gastroenterol; 1984 Jun; 19(4):531-4. PubMed ID: 6463577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination.
    Solomon MJ; McLeod RS
    CMAJ; 1994 Jun; 150(12):1961-70. PubMed ID: 7980760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilizing television to promote a community colon cancer screening program.
    Bloch S; Ashwanden P; Neugut AI; Field M; Rubin M; Apfelbaum T; Rubinoff M; Weinstein IB
    Prog Clin Biol Res; 1990; 339():311-23. PubMed ID: 2392428
    [No Abstract]   [Full Text] [Related]  

  • 36. Mass screening for colorectal cancer--the Philadelphia experience.
    Frazier TG; Bassett JG; Weiss SM; Zimmelman S
    J Cancer Educ; 1987; 2(1):31-3. PubMed ID: 3274967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experience with screening for colorectal carcinoma using the Haemoccult Test].
    Zoubek V; Zoubková H
    Cesk Zdrav; 1989 Mar; 37(3):117-21. PubMed ID: 2720834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pros and cons of a mass-media colorectal screening program.
    Cole RE; Wagner DE
    Prog Clin Biol Res; 1990; 339():325-30. PubMed ID: 2118258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program.
    Petrelli N; Michalek AM; Freedman A; Baroni M; Mink I; Rodriguez-Bigas M
    Surg Oncol; 1994 Feb; 3(1):27-36. PubMed ID: 8186868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mass screening for colorectal cancer.
    Khubchandani IT; Karamchandani MC; Kleckner FS; Sheets JA; Stasik JJ; Rosen L; Riether RD
    Dis Colon Rectum; 1989 Sep; 32(9):754-8. PubMed ID: 2503341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.